Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,780.00
(
-0.07%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.44
(
-2.01%
)
Bitcoin
70,421.25
(
-1.15%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 100076

Thursday, 07/29/2010 8:41:41 AM

Thursday, July 29, 2010 8:41:41 AM

Post# of 257262
From SNY’s 2Q10 PR today:

http://en.sanofi-aventis.com/binaries/20100729_Q2_2010_Results2_en_tcm28-29020.pdf

On July 23, 2010, the Company learned that the FDA had approved a generic enoxaparin ANDA. As a result of this ANDA approval, first half 2010 sales of Lovenox® in the United States should not be considered indicative of [Sanofi-Aventis’] future U.S. sales.

LOL

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now